220 related articles for article (PubMed ID: 32130941)
41. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
42. Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits.
Schnute ME; McReynolds MD; Carroll J; Chrencik J; Highkin MK; Iyanar K; Jerome G; Rains JW; Saabye M; Scholten JA; Yates M; Nagiec MM
J Med Chem; 2017 Mar; 60(6):2562-2572. PubMed ID: 28231433
[TBL] [Abstract][Full Text] [Related]
43. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
44. Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.
Fernandes Â; Azevedo MM; Pereira O; Sampaio-Marques B; Paiva A; Correia-Neves M; Castro I; Ludovico P
Oncotarget; 2015 Oct; 6(31):31428-40. PubMed ID: 25537507
[TBL] [Abstract][Full Text] [Related]
45. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
46. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
47. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
48. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.
Dick TE; Hengst JA; Fox TE; Colledge AL; Kale VP; Sung SS; Sharma A; Amin S; Loughran TP; Kester M; Wang HG; Yun JK
J Pharmacol Exp Ther; 2015 Mar; 352(3):494-508. PubMed ID: 25563902
[TBL] [Abstract][Full Text] [Related]
49. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families.
Li L; Meyer C; Zhou ZW; Elmezayen A; Westover K
J Mol Biol; 2022 Sep; 434(17):167626. PubMed ID: 35595166
[TBL] [Abstract][Full Text] [Related]
51. Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization.
Hengst JA; Hegde S; Paulson RF; Yun JK
Bioorg Med Chem Lett; 2020 Oct; 30(20):127453. PubMed ID: 32736077
[TBL] [Abstract][Full Text] [Related]
52. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
53. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Sun D; Yang Y; Lyu J; Zhou W; Song W; Zhao Z; Chen Z; Xu Y; Li H
J Med Chem; 2016 Jul; 59(13):6187-200. PubMed ID: 27266526
[TBL] [Abstract][Full Text] [Related]
54. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity.
Ferguson FM; Doctor ZM; Ficarro SB; Browne CM; Marto JA; Johnson JL; Yaron TM; Cantley LC; Kim ND; Sim T; Berberich MJ; Kalocsay M; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):804-817.e12. PubMed ID: 30930164
[TBL] [Abstract][Full Text] [Related]
55. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
56. The target landscape of clinical kinase drugs.
Klaeger S; Heinzlmeir S; Wilhelm M; Polzer H; Vick B; Koenig PA; Reinecke M; Ruprecht B; Petzoldt S; Meng C; Zecha J; Reiter K; Qiao H; Helm D; Koch H; Schoof M; Canevari G; Casale E; Depaolini SR; Feuchtinger A; Wu Z; Schmidt T; Rueckert L; Becker W; Huenges J; Garz AK; Gohlke BO; Zolg DP; Kayser G; Vooder T; Preissner R; Hahne H; Tõnisson N; Kramer K; Götze K; Bassermann F; Schlegl J; Ehrlich HC; Aiche S; Walch A; Greif PA; Schneider S; Felder ER; Ruland J; Médard G; Jeremias I; Spiekermann K; Kuster B
Science; 2017 Dec; 358(6367):. PubMed ID: 29191878
[TBL] [Abstract][Full Text] [Related]
57. A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinases.
Sharma LK; Leonardi R; Lin W; Boyd VA; Goktug A; Shelat AA; Chen T; Jackowski S; Rock CO
J Med Chem; 2015 Feb; 58(3):1563-8. PubMed ID: 25569308
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets.
Al-Ghabkari A; Perinpanayagam MA; Narendran A
Curr Cancer Drug Targets; 2019; 19(10):828-837. PubMed ID: 30914027
[TBL] [Abstract][Full Text] [Related]
60. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.
Orr Gandy KA; Obeid LM
Biochim Biophys Acta; 2013 Jan; 1831(1):157-66. PubMed ID: 22801037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
